Table 3. ORR and DCR with various treatments for patient with ROS1-positive NSCLC.
| Treatment (n = 68) | ORR (%) | DCR (%) | Not evaluated |
|---|---|---|---|
| A. Received ROS1 TKI in 1L (n = 38)b | 29/38 (76.32%) | 34/38 (89.47%) | 4/38 (10.53%) |
| 1. ROS1 TKI alone (n = 12)b | 10/12 (83.33%) | 10/12 (83.33%) | 2/12 (16.67%) |
| a. Crizotinib (n = 9) | 9/9a (100%) | 9/9a (100%) | – |
| b. Entrectinib (n = 1)b | – | – | 1/1 (100%) |
| c. Ceritinib (n = 2)b | 1/2 (50%) | 1/2(50%) | 1/2(50%) |
| 2. Chemotherapy followed by ROS1 TKI (n = 21)b | 15/21 (71.43%) | 19/21 (90.48%) | 2/21 (9.52%) |
| 3. Chemo-immunotherapy followed by ROS1 TKI (n = 3) | 2/3 (66.67%) | 3/3 (100%) | – |
| 4. EGFR TKI + ROS1 TKI (n = 1) | 1/1 (100%) | 1/1 (100%) | – |
| 5. Chemo-bevacizumab followed by ROS1 TKI (n = 1) | 1/1 (100%) | 1/1 (100%) | – |
| B. Systemic therapies other than ROS1 TKI in 1L | 12/29 (41.38%) | 20/29 (68.97%) | |
| 1. Chemotherapy only (Pemetrexed-carboplatin)c | 11/20 (55%) | 18/20 (90%) | – |
| 2. Pemetrexed-carboplatin-bevacizumab | 1/1 (100%) | 1/1 (100%) | – |
| 3. EGFR TKId | 0/8 (0%) | 1/8 (12.5%) | – |
| C. No treatment | 0/1 | 0/1 |
a
One patient achieved complete metabolic response on crizotinib
b
Not evaluated radiologically: 4 = 1 patient on entrectinib and ceritinib each +2 patients on crizotinib after initial chemotherapy
c
Two patients progressed clinically. No response scan was done
d
One patient had stable disease on CT scan and defaulted post first follow up while seven others progressed clinically and no response scan was done
EGFR = Epidermal growth factor receptor; TKI= Tyrosine kinase inhibitor